COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00122837




Registration number
NCT00122837
Ethics application status
Date submitted
20/07/2005
Date registered
22/07/2005
Date last updated
18/10/2007

Titles & IDs
Public title
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
Scientific title
A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
Secondary ID [1] 0 0
F1J-MC-HMDW
Secondary ID [2] 0 0
7106
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anxiety Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Anxiety

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Duloxetine
Treatment: Drugs - venlafaxine
Treatment: Drugs - placebo

Treatment: Drugs: Duloxetine


Treatment: Drugs: venlafaxine


Treatment: Drugs: placebo


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Assess whether duloxetine hydrochloride 60 to 120 mg QD is superior to placebo in the treatment of GAD, defined as statistically greater reduction in anxiety symptoms as measured by the HAMA
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Self-reported anxiety symptomatology
Timepoint [1] 0 0
Secondary outcome [2] 0 0
Quality of Life
Timepoint [2] 0 0
Secondary outcome [3] 0 0
Clinical Global Improvement
Timepoint [3] 0 0
Secondary outcome [4] 0 0
HAMA factor scores
Timepoint [4] 0 0

Eligibility
Key inclusion criteria
- Male and female outpatients at least 18 years of age, presenting with generalized
anxiety disorder (GAD).
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any current and primary Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) Axis I diagnosis other than GAD. Patients diagnosed with major
depressive disorder within the past 6 months -or- patients diagnosed with panic
disorder, post-traumatic stress disorder, or an eating disorder within the past year
-or- obsessive-compulsive disorder, bipolar affective disorder, psychosis factitious
disorder, or somatoform disorders during their lifetime

- The presence of an Axis II disorder or history of antisocial behavior, which in the
judgement of the investigator would interfere with compliance with study protocol

- Have previously completed or withdrawn from this study or any other study
investigating duloxetine or have previously been treated with duloxetine

- History of alcohol or any psychoactive substance abuse or dependence (as defined in
the DSM-IV-TR) within the past 6 months

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Everton Park
Recruitment hospital [2] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Spring Hill
Recruitment hospital [3] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Toowoomba
Recruitment hospital [4] 0 0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test - Armadale
Recruitment postcode(s) [1] 0 0
4053 - Everton Park
Recruitment postcode(s) [2] 0 0
4000 - Spring Hill
Recruitment postcode(s) [3] 0 0
4350 - Toowoomba
Recruitment postcode(s) [4] 0 0
3143 - Armadale
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Cordoba
Country [3] 0 0
Argentina
State/province [3] 0 0
Rosario
Country [4] 0 0
Belgium
State/province [4] 0 0
Liège
Country [5] 0 0
Belgium
State/province [5] 0 0
Tielt
Country [6] 0 0
Canada
State/province [6] 0 0
British Columbia
Country [7] 0 0
Canada
State/province [7] 0 0
Manitoba
Country [8] 0 0
Canada
State/province [8] 0 0
Ontario
Country [9] 0 0
Mexico
State/province [9] 0 0
Mexico City
Country [10] 0 0
Mexico
State/province [10] 0 0
San Luis Potosi
Country [11] 0 0
Russian Federation
State/province [11] 0 0
Moscow
Country [12] 0 0
Taiwan
State/province [12] 0 0
Changhua
Country [13] 0 0
Taiwan
State/province [13] 0 0
Taichung
Country [14] 0 0
Taiwan
State/province [14] 0 0
Taipei
Country [15] 0 0
Taiwan
State/province [15] 0 0
Tao-Yuan
Country [16] 0 0
United Kingdom
State/province [16] 0 0
Scotland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Boehringer Ingelheim
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a clinical trial assessing duloxetine and comparator to placebo in patients who have
generalized anxiety disorder.
Trial website
https://clinicaltrials.gov/show/NCT00122837
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications